Search
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigationalcontain an imide group. … [A228553] It is a 4-amino-glutamyl analogue of [thalidomide] [A228543] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms.
Categories: P-glycoprotein substratesTizanidine
go.drugbank.com/drugs/DB00697ApprovedInvestigationalTizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. … Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.
Mixtures: ALERTADINA® A TABLETAS RECUBIERTASCategories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesCariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigational[A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18. … [A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a reduction
Alglucerase
go.drugbank.com/drugs/DB00088ApprovedWithdrawnThe modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues.
Trastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: Enhertu 100 mg IV İnfüzyonluk Çözelti Hazırlamada Kullanılacak Konsantre İçin Toz, 1 ADETOnasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigationalDeveloped by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion. … [A187250] As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms.
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigationalLonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone ([somatropin]) indicated for the treatment of children 1 year and older, weighing at least … [A237605,L36380,L36405] Unlike somatropin, which requires daily dosing, lonapegsomatropin can be administered as a single weekly dose.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersGuselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalGuselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. … IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357].
Products: TREMFYA IV